CARDIOPRECISION LTD

CARDIOPRECISION LTD is a MedTech startup based in the United Kingdom, established in 2007 with a focus on advancing cardiovascular solutions. The company specializes in developing medical technology and products for minimally invasive treatment of structural heart disease. Its innovative transcervical approach for minimally invasive aortic valve surgery and interventions has gained attention, offering benefits such as reduced pain, faster recovery, lower blood loss, and shorter hospital stays. Notably, CardioPrecision has introduced CoreVista® devices that have been successfully utilized in both Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) procedures. Moreover, the company has launched a suite of CoreVista® devices for use in Endoscopic Vessel Harvesting (EVH) during coronary artery bypass grafting (CABG) surgery, marking a significant milestone during the peak of the Covid pandemic. The company's last investment, a Venture Round investment at 31 October 2022, involved notable investors including Scottish Enterprise, London & Scottish Investment Partners, Scottish Health Innovations, and Discovery Investment Fund. With its dedication to enhancing patients' lives through innovative and less invasive access solutions for cardiothoracic surgery and cardiovascular interventions, CardioPrecision holds promising potential for growth and impact in the Health Care industry.